An FDA panel voted yes on BPC-157. It's still not legal to compound.
In July, FDA's compounding advisory committee narrowly backed BPC-157, TB-500 and MOTS-c. The vote is only advice, FDA's own reviewers had doubts, and sport rules haven't changed.
News
Peptide news, minus the hype.
FDA decisions, new trials and anti-doping rules, explained in plain language with the sources linked.
Introducing the Peptide Evidence Scorecard
One page that grades every peptide we cover on human evidence, FDA status and sport status, with the sources one click away.
Retatrutide's first phase 3 results: about a quarter of body weight lost
The TRIUMPH-1 trial of Eli Lilly's triple-hormone drug reported up to 25% average weight loss over 80 weeks. It isn't approved yet, and FDA has warned companies selling it online.